Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen Polypeptide Vaccine in Advanced Solid Tumors
NCT06195293Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2024
- Primary completion
- Dec 2029
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neoantigen polypeptide immunomodulator in solid tumor, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Dose Limiting Toxicity at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
neoantigen polypeptide immunomodulator
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06195293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195293.